Clorox Co (CLX) Shares Sold by Creative Planning

Creative Planning reduced its stake in shares of Clorox Co (NYSE:CLX) by 7.4% during the 1st quarter, HoldingsChannel reports. The firm owned 19,375 shares of the company’s stock after selling 1,539 shares during the period. Creative Planning’s holdings in Clorox were worth $3,109,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Visionary Asset Management Inc. purchased a new stake in shares of Clorox in the 4th quarter worth about $225,000. Phocas Financial Corp. purchased a new stake in shares of Clorox in the 4th quarter worth about $193,000. Oregon Public Employees Retirement Fund raised its stake in Clorox by 48,033.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,808,980 shares of the company’s stock valued at $44,000 after purchasing an additional 6,794,834 shares during the last quarter. Deutsche Bank AG raised its stake in Clorox by 10.2% in the 4th quarter. Deutsche Bank AG now owns 307,703 shares of the company’s stock valued at $47,425,000 after purchasing an additional 28,361 shares during the last quarter. Finally, Montecito Bank & Trust raised its stake in Clorox by 24.0% in the 1st quarter. Montecito Bank & Trust now owns 5,212 shares of the company’s stock valued at $836,000 after purchasing an additional 1,009 shares during the last quarter. Institutional investors own 76.94% of the company’s stock.

In other news, SVP Matthew T. Laszlo sold 10,585 shares of the company’s stock in a transaction dated Wednesday, February 6th. The shares were sold at an average price of $153.89, for a total transaction of $1,628,925.65. Following the completion of the transaction, the senior vice president now owns 17,994 shares of the company’s stock, valued at approximately $2,769,096.66. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Andrew J. Mowery sold 5,340 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $156.44, for a total transaction of $835,389.60. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

NYSE CLX opened at $157.56 on Monday. Clorox Co has a 12 month low of $115.00 and a 12 month high of $167.70. The company has a debt-to-equity ratio of 3.08, a current ratio of 1.15 and a quick ratio of 0.66. The stock has a market cap of $20.19 billion, a PE ratio of 25.17, a P/E/G ratio of 4.09 and a beta of 0.32.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Monday, February 4th. The company reported $1.40 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.08. Clorox had a net margin of 12.65% and a return on equity of 105.97%. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.47 billion. During the same quarter in the prior year, the company posted $1.77 EPS. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. On average, analysts expect that Clorox Co will post 6.3 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Stockholders of record on Wednesday, April 24th will be paid a dividend of $0.96 per share. This represents a $3.84 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date of this dividend is Tuesday, April 23rd. Clorox’s dividend payout ratio is currently 61.34%.

CLX has been the subject of several analyst reports. Zacks Investment Research downgraded shares of Clorox from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Wells Fargo & Co reissued a “hold” rating and issued a $157.00 target price on shares of Clorox in a research note on Monday, February 4th. Citigroup set a $171.00 target price on shares of Clorox and gave the company a “hold” rating in a research note on Tuesday, February 5th. JPMorgan Chase & Co. downgraded shares of Clorox from a “neutral” rating to an “underweight” rating and cut their target price for the company from $159.00 to $139.00 in a research note on Monday, April 8th. Finally, BMO Capital Markets set a $175.00 target price on shares of Clorox and gave the company a “buy” rating in a research note on Tuesday, February 5th. Five research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $151.21.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://sportsperspectives.com/2019/04/29/clorox-co-clx-shares-sold-by-creative-planning.html.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Article: S&P 500 Index

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.